We have detected you are coming from a location outside of Germany.
Wir haben festgestellt, dass Sie von einem Standort außerhalb Deutschlands auf diese Seite gelangt sind.

Please select your preferred language:
Bitte wählen Sie eine der folgenden Sprachoptionen:
  • Zurück
  • Startseite
  • Mediathek
  • Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database

Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database

Autor: Dominguez-Valentin M, Sampson J, FMedSci, [...], Holinski-Feder E, Morak M, [...], Steinke-Lange V, et al.
|
Veröffentlichungsdatum: 24.07.2019

Zugehörige Fachbereiche

Onkologie

PURPOSE: Pathogenic variants affecting MLH1, MSH2, MSH6, and PMS2 cause Lynch syndrome and result in different but imprecisely known cancer risks. This study aimed to provide age and organ-specific cancer risks according to gene and gender and to determine survival after cancer.

METHODS: We conducted an international, multicenter prospective observational study using independent test and validation cohorts of carriers of class 4 or class 5 variants. After validation the cohorts  were merged providing 6350 participants and 51,646 follow-up years.

RESULTS: There were 1808 prospectively observed cancers. Pathogenic MLH1 and MSH2 variants caused high penetrance dominant cancer syndromes sharing similar colorectal, endometrial, and ovarian cancer risks, but older MSH2 carriers had higher risk of cancers of the upper urinary tract, upper gastrointestinal tract, brain, and particularly prostate. Pathogenic MSH6 variants caused a sex-limited trait with high endometrial cancer risk but only modestly increased colorectal cancer risk in both genders. We did not demonstrate a significantly increased cancer risk in  carriers of pathogenic PMS2 variants. Ten-year crude survival was over 80% following colon, endometrial, or ovarian cancer.

CONCLUSION: Management guidelines for Lynch syndrome may require revision in light of these different gene and gender-specific risks and the good prognosis for the most commonly associated cancers.

Genet Med. 2019

https://doi.org/10.1038/s41436-019-0596-9

Es wurden keine Änderungen des Artikels vorgenommen.

http://creativecommons.org/licenses/by-nc-sa/4.0/

 

Die Publikation steht Ihnen im Folgenden zum Download bereit:

Zugehörige Fachbereiche

Onkologie